Research programme: Staphylococcus aureus monoclonal antibodies - Valneva/Merck

Drug Profile

Research programme: Staphylococcus aureus monoclonal antibodies - Valneva/Merck

Alternative Names: S.aureus monoclonal antibodies - Intercell/Merck

Latest Information Update: 27 Jun 2013

Price : $50

At a glance

  • Originator Intercell; Merck & Co
  • Developer Intercell; Merck & Co; Valneva
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Staphylococcal infections
  • Discontinued Streptococcal infections

Most Recent Events

  • 27 Jun 2013 No development reported - Preclinical for Staphylococcal infections in Austria (Parenteral)
  • 27 Jun 2013 No development reported - Preclinical for Staphylococcal infections in USA (Parenteral)
  • 28 May 2013 Intercell has merged with Vivalis to form Valneva
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top